

## Originalarbeiten, Kardiometabolische Erkrankungen (ab 1997)

1. Leiherer A, Muendlein A, Saely CH, Kinz E, Brandtner EM, Fraunberger P, Drexel H. Serum uromodulin is associated with impaired glucose metabolism. *Medicine (Baltimore)*. 2017 Feb;96(5): PMID: 28151855
2. Leiherer A, Muendlein A, Saely CH, Ebner J, Brandtner EM, Fraunberger P, Drexel H. Serum uromodulin is a predictive biomarker for cardiovascular events and overall mortality in coronary patients. *Int J Cardiol*. 2016 Dec 29. pii: S0167-5273(16)32602-X. PMID: 28089453
3. Gitt AK, Lautsch D, Ferrieres J, Kastelein J, Drexel H, Horack M, Brudi P, Vanneste B, Bramlage P, Chazelle F, Sazonov V, Ambegaonkar B. Contemporary data on low-density lipoprotein cholesterol target value attainment and distance to target in a cohort of 57,885 statin-treated patients by country and region across the world. *Data Brief*. 2016 Sep 29;9:616-620. PMID: 27766290
4. Gitt AK, Lautsch D, Ferrieres J, Kastelein J, Drexel H, Horack M, Brudi P, Vanneste B, Bramlage P, Chazelle F, Sazonov V, Ambegaonkar B. Low-density lipoprotein cholesterol in a global cohort of 57,885 statin-treated patients. *Atherosclerosis*. 2016 Dec;255:200-209.
5. Jaeger T, Muendlein A, Hodaie J, Untergasser G, Steurer M, Saely CH, Drexel H, Lang AH. Prevalence of calreticulin exon 9 indel mutations in vascular risk patients. *Thromb Res*. 2016 Aug;144:215-7 PMID: 27423004
6. Vonbank A, Saely CH, Rein P, Zanolin D, Drexel H. Lipoprotein (a), the Metabolic Syndrome and Vascular Risk in Angiographed Coronary Patients. *JCEM* 2016 Aug;101(8):3199-203.
7. Leiherer A, Stoemmer K, Muendlein A, Saely CH, Kinz E, Brandtner EM, Fraunberger P, Drexel H. Quercetin impacts expression of metabolism - and obesity-associated genes in SGBS adipocytes. *Nutrients* 2016; 8: E282.
8. Saely CH, Leiherer A, Muendlein A, Vonbank A, Rein P, Geiger K, Malin C, Drexel H. Coronary patients with high plasma omentin are at a higher cardiovascular risk. *Data in Brief* 2015; 6:158-61.
9. Naerr G, Rein P, Saely CH, Drexel D. Effects of synthetic and biological disease modifying antirheumatic drugs on lipid and lipoprotein parameters in patients with rheumatoid arthritis. *Vascular Pharmacology* 2016; 81: 22-30.
10. Mueller DM; Allenspach M, Othman A, Saely CH, Muendlein A, Vonbank A, Drexel H, von Eckardstein A. Plasma levels of trimethylamine-N-oxide are confounded by impaired kidney function and poor metabolic control. *Atherosclerosis* 2015; 243: 638-644.
11. Saely CH, Leiherer A, Muendlein A, Vonbank A, Rein P, Geiger K, Malin C, Drexel H. High plasma omentin predicts cardiovascular events independently from the presence and extent of angiographically determined atherosclerosis. *Atherosclerosis* 2016; 244: 38-43.

12. Leiherer A, Muendlein A, Kinz E, Vonbank A, Rein P, Fraunberger P, Malin C, Saely CH, Drexel H. High plasma chemerin is associated with renal dysfunction and predictive for cardiovascular events - Insights from phenotype and genotype characterization. *Vascular Pharmacology* 2016; 77:60-8.
13. Vonbank A, Saely CH, Rein P, Drexel H. Lipid Parameters in Patients with Acute Coronary Syndromes versus Stable Coronary Artery Disease. *Eur J Clin Invest* 2015; 45: 1092-1097.
14. Muendlein A, Leiherer A, Saely CH, Rein P, Zanolin D, Kinz E, Brandtner EM, Fraunberger P, Drexel H. Common single nucleotide polymorphisms at the NPC1L1 gene locus significantly predict cardiovascular risk in coronary patients. *Atherosclerosis* 2015; 242: 340-345.
15. Silbernagel G, Rein P, Saely CH, Engelberger RP, Willenberg T, Do DD, Kucher N, Baumgartner I, Drexel H. Prevalence of Type 2 Diabetes Is Higher in Peripheral Artery Disease than in Coronary Artery Disease Patients. *Diab Vasc Dis Res* 2015; 12: 146-9.
16. Wirth K, Peter RS, Saely CH, Concin H, Nagel G. Long-term weight change: association with impaired glucose metabolism in young austrian adults. *PLoS One* 2015; 10: e0127186.
17. Othman A, Saely CH, Muendlein A, Vonbank A, Drexel H, von Eckardstein A, Hornemann T. Plasma C20- Sphingolipids predict cardiovascular events independently from conventional cardiovascular risk factors in patients undergoing coronary angiography. *Atherosclerosis* 2015; 240: 216-21.
18. Rein P, Saely CH, Vonbank A, Fraunberger P, Drexel H. Is albuminuria a myocardial infarction risk equivalent for atherothrombotic events? *Atherosclerosis*. 2015 May;240(1):21-5. PubMed PMID: 25746373.
19. Othman A, Saely CH, Muendlein A, Vonbank A, Drexel H, von Eckardstein A, Hornemann T. Plasma 1-deoxysphingolipids are predictive biomarkers for type 2 diabetes mellitus. *BMJ Open Diabetes Research & Care* 2015; 3: e000073.
20. Rein P., Saely Ch., Silbernagel G., Vonbank A., Mathies R., Drexel H. Baumgartner I. Systemic inflammation is higher in peripheral artery disease than in coronary artery disease *Atherosclerosis* 2015; 239: 299-303.
21. Brian Salmons; Eva Maria Brandtner; John A Dangerfield, Walter H Gunzburg: Encapsulation of Insulin Producing Cells for Diabetes Treatment Using Alginate and Cellulose Sulphate as Bioencapsulation Polymers. *Diabetes Research and Treatment* 2014; 1: 1-7.
22. Muendlein A, Kinz E Gasser K, Leiherer A, Rein P, Saely CH, Grallert H, Peters A, Fraunberger P, Drexel H, Lang AH. Occurrence of the JAK2 V617F mutation in patients with peripheral arterial disease. *Am J Hem* 2015; 90: E17-21.
23. Muendlein A, Leiherer A, Kinz E, Rein P, Vonbank A, Zanolin D, Malin C, Drexel H, Saely CH, Fraunberger P. Angiotensin-like protein 4 significantly predicts future cardiovascular events in coronary patients. *Atherosclerosis* 2014; 237: 632-638.

24. Leiherer A, Muendlein A, Rein P, Saely CH, Kinz E, Fraunberger P, Drexel H. Genome-wide association study reveals a polymorphism in the podocyte receptor RANK for the decline of renal function in coronary patients. *PLoS One* 2014; 9: e114240.
25. Biller K, Fae P, Germann R, Drexel H, Walli AK, Fraunberger P. Cholesterol rather than PCT or CRP predicts mortality in patients with infection Shock: Injury, Inflammation, and Sepsis 2014; 42: 129-132.
26. Chan K, Patel RS, Newcombe P, Nelson CP, Qasim A, Epstein SE, Burnett S, Vaccarino VL, Zafari AM, Shah SH, Anderson JL, Carlquist JF, Hartiala J, Allayee H, Hinohara K, Lee BS, Erl A, Ellis KL, Goel A, Schaefer AS, El Mokhtari NE, Goldstein BA, Hlatky MA, Go AS, Shen GQ, Gong Y, Pepine C, Laxton RC, Whittaker JC, Tang WH, Johnson JA, Wang QK, Assimes TL, Nöthlings U, Farrall M, Watkins H, Richards AM, Cameron VA, Muendlein A, Drexel H, Koch W, Park JE, Kimura A, Shen WF, Simpson IA, Hazen SL, Horne BD, Hauser ER, Quyyumi AA, Reilly MP, Samani NJ, Ye S. Association between the chromosome 9p21 locus and angiographic coronary artery disease burden: a collaborative meta-analysis. *J Am Coll Cardiol* 2013: 957-
27. Puig L, Strohal R, Fuimann J, Pedersen R, Szumski A, Koenig AS, Robertson D, Drexel H. Cardiometabolic biomarkers in chronic plaque psoriasis before and after etanercept treatment. *J Dermatol Treatment* 2013; 25: 470-481.
28. Leiherer A, Geiger K, Muendlein A, Drexel H. Hypoxia induces a HIF-1 $\alpha$  dependent signaling cascade to make a complex metabolic switch in SGBS-adipocytes. *Mol Cell Endocrinol* 2013; 383: 21-31.
29. Muendlein A, Gasser K, Kinz E, Stark N, Leiherer A, Rein P, Saely CH, Grallert H, Peters A, Drexel H, Lang AH. Evaluation of the prevalence and prospective clinical impact of the JAK2 V617F mutation in coronary patients. *Am J Hematol*. 2013; 89: 295-301.
30. Höliner I, Haslinger V, Lütchg J, Müller G, Seick Barbarini D, Fussenegger J, Zanier U, Saely CH, Drexel H, Simma B. Validity of the Neurological Examination in Diagnosing Diabetic Peripheral Neuropathy. *Ped Neurol* 2013; 49:171-177.
31. Vonbank A, Saely CH, Rein P, Sturn D, Drexel H. Current cholesterol guidelines and clinical reality: a comparison of two cohorts of coronary artery disease patients *Swiss Med Wkly* 2013; 143: w13827.
32. Rein P, Saely CH, Vonbank A, Fraunberger P, Drexel H. Impact of the albumin to creatinine ratio and the coronary artery state on vascular events: Is Albuminuria a coronary artery disease equivalent? *Am J Cardiol* 2014; 113: 1616-1620.
33. Saely CH, Drexel H. Is Type 2 Diabetes Really a Coronary Heart Disease Risk Equivalent? *Vasc Pharmacol* 2013; 59: 11-18.
34. Vonbank A, Saely CH, Rein P, Drexel H. Insulin resistance is significantly associated with the metabolic syndrome, but not with sonographically proven peripheral arterial disease. *Cardiovasc. Diabetol* 2013; 12: 106.

35. Rein P, Saely CH, Vonbank A, Boehnel C, Drexel H. Serial Decline of kidney function predicts total mortality and cardiovascular events in coronary artery disease. *Am J Cardiol* 2014; 113: 215-221.
36. Eber B, Lautsch D, Fauer C, Drexel H, Pfeiffer KP, Traindl O, Pichler M. Can LDL-cholesterol targets be achieved in a population at high risk? Results of the non-interventional study ACT II. *Curr Med Res Opin* 2012; 28: 1447-1454.
37. Mann E, Vonbank A, Drexel H, Saely CH. Diabetes care among older adults in primary care in Austria: a cross-sectional study. *Swiss Med Wkly* 2012; 142: w13646.
38. Zeppetbauer M, Drexel H, Vonbank A, Rein P, Aczel S, Saely CH. Eccentric endurance exercise economically improves metabolic and inflammatory risk factors. *Eur J Prev Cardiol* 2013; 20: 577-584.
39. Pichler M, Lautsch D, Adler C, Bögl K, Drexel H, Eber B, Fauer C, Föchterle J, Föger B, Gansch K, Grafinger P, Lechleitner M, Ludvik B, Maurer G, Mörz R, Paulweber B, Pfeiffer KP, Prager R, Stark G, Toplak H, Traindl O, Weitgasser R. Are there differences in LDL-C target value attainment in Austrian federal states? Yes! *Wien Med Wochenschr* 2013; 163: 528-535. PMID: 23979353
40. Saely CH, Rein P, Vonbank A, Huber K, Drexel H. Type 2 diabetes and the progression of visualized atherosclerosis to clinical cardiovascular events. *Int J Cardiol* 2013; 167: 776-780.
41. Lautsch D, Saely CH, Traindl O, Eber B, Pfeiffer KP, Drexel H. Is there a link between non-HDL cholesterol and blood pressure? An age and gender directed analysis of 7500 hypertensive outpatients. *J Kardiol* 2012;19:11-16.
42. Othman A, Ruetti MF, Ernst D, Saely CH, Rein P, Drexel H, Porretta-Serapiglia, Lauria G, Bianchi R, von Eckardstein A, Hornemann T. Plasma deoxysphingolipids: a novel class of biomarkers for the metabolic syndrome? *Diabetologia* 2012;55:421-431.
43. Muendlein A, Stark N, Rein P, Saely CH, Geller-Rhomberg S, Geiger K, Vonbank A, Drexel H. Are AHSN polymorphisms directly associated with coronary atherosclerosis? *Clin Chim Acta* 2012;413:287-290.
44. Gitt AK, Drexel H, Feely J, Ferrières J, Gonzalez-Juanatey JR, Thomsen KK, Leiter LA, Lundmann P, da Silva PM, Pedersen T, Wood D, Juenger C, Dellea PS, Sazonov V, Chazelle F, Kastelein JJ. Persistent lipid abnormalities in statin-treated patients and predictors of LDL-cholesterol goal
45. Steiner C, Othman A, Saely CH, Rein P, Drexel H, von Eckardstein A, Rentsch KM. Bile acid metabolites in serum: intraindividual variation and associations with coronary heart disease, metabolic syndrome and diabetes mellitus. *PLoS One* 2011;6:e25006.
46. Geiger K, Leiberer A, Muendlein A, Stark N, Geller-Rhomberg S, Saely CH, Wabitsch M, Fraunberger P, Drexel H. Identification of hypoxia-induced genes in human SGBS adipocytes by microarray analysis. *PLoS One* 2011;6:e26465.

47. Drexel H, Chazelle F, Fauer C, Lautsch D, Gitt AK. Persistent dyslipidemia in Austrian patients treated with statins for primary and secondary prevention of atherosclerotic events - Results of the DYSlipidemia International Study (DYSIS). *Wien Klin Wochenschr* 2011;123:611-617.
48. Leiter LA, Lundman P, da Silva PM, Drexel H, Juenger C, Gitt AK. Persistent lipid abnormalities in statin-treated patients with diabetes mellitus in Europe and Canada: results of the Dyslipidaemia International Study. *Diabet Med* 2011;28:1343-1351.
49. Geiger K, Muendlein A, Stark N, Saely CH, Wabitsch M, Fraunberger P, Drexel H. Hypoxia induces apelin expression in human adipocytes. *Horm Metab Res* 2011;43:380-385.
50. Muendlein A, Saely CH, Geller-Rhomberg S, Sonderegger G, Rein P, Winder T, Beer S, Vonbank A, Drexel H. Single nucleotide polymorphisms of TCF7L2 are linked to diabetic coronary atherosclerosis. *PLoS One* 2011;6:e17978.
51. Rein P, Vonbank A, Saely CH, Beer S, Jankovic V, Boehnel C, Breuss J, Risch L, Fraunberger P, Drexel H. Relation of albuminuria to angiographically determined coronary arterial narrowing in patients with and without type 2 diabetes mellitus and stable or suspected coronary artery disease. *Am J Cardiol* 2011;107:1144-1148.
52. Vonbank A, Saely CH, Rein P, Beer S, Breuss J, Boehnel C, Drexel H. Insulin resistance is associated with the metabolic syndrome and is not directly linked to coronary artery disease. *Clin Chim Acta* 2011;412:1003-1007.
53. Saely CH, Vonbank A, Drexel H. HDL cholesterol and residual risk of first cardiovascular events. *Lancet* 2010;376:1738-1739.
54. Rein P, Saely CH, Beer S, Vonbank A, Drexel H. Roles of the metabolic syndrome, HDL cholesterol, and coronary atherosclerosis in subclinical inflammation. *Diabetes Care* 2010;33:1853-1855.
55. Sourij H, Saely CH, Schmid F, Zweiker R, Marte T, Wascher TC, Drexel H. Post-challenge hyperglycaemia is strongly associated with future macrovascular events and total mortality in angiographed coronary patients. *Eur Heart J* 2010;31:1583-1590.
56. Rein P, Saely CH, Muendlein A, Vonbank A, Drexel H. Serial decline of kidney function as a novel biomarker for the progression of atherothrombotic disease. *Atherosclerosis* 2010;211:348-352.
57. Saely CH, Aczel S, Koch L, Schmid F, Marte T, Huber K, Drexel H. Diabetes as a coronary artery disease risk equivalent: before a change of paradigm? *Eur J Cardiovasc Prev Rehabil* 2010;17:94-99.
58. Beer S, Saely CH, Hoefle G, Rein P, Vonbank A, Breuss J, Gaensbacher B, Muendlein A, Drexel H. Low bone mineral density is not associated with angiographically determined coronary atherosclerosis in men. *Osteoporos Int* 2010;21:1695-1701.

59. Drexel H, Aczel S, Marte T, Vonbank A, Saely CH. Factors predicting cardiovascular events in statin-treated diabetic and non-diabetic patients with coronary atherosclerosis. *Atherosclerosis* 2010;208:484-489.
60. Saely CH, Eber B, Pfeiffer KP, Drexel H. Low serum LDL cholesterol in patients with type 2 diabetes: an analysis on two different patient populations. *Int J Cardiol* 2010;144:394-398.
61. Saely CH, Rein P, Vonbank A, Drexel H. Serum levels of C-reactive protein in patients with stable coronary artery disease: JUPITER in perspective. *Int J Cardiol* 2010;144:448-449.
62. Rein P, Beer S, Saely CH, Vonbank A, Drexel H. Prevalence of impaired glucose metabolism in individuals with peripheral arterial disease. *Int J Cardiol* 2010;144:243-244.
63. Saely CH, Risch L, Frey F, Lupi GA, Leuppi JD, Drexel H, Huber AH. Body mass index, blood pressure, and serum cholesterol in young Swiss men: an analysis on 56784 army conscripts. *Swiss Med Wkly* 2009;139:518-524.
64. Muendlein A, Geller-Rhomberg S, Saely CH, Winder T, Sonderegger G, Rein P, Beer S, Vonbank A, Drexel H. Significant impact of chromosomal locus 1p13.3 on serum LDL cholesterol and on angiographically characterized coronary atherosclerosis. *Atherosclerosis* 2009;206:494-499.
65. Muendlein A, Saely CH, Rhomberg S, Sonderegger G, Loacker S, Rein P, Beer S, Vonbank A, Winder T, Drexel H. Evaluation of the association of genetic variants on the chromosomal loci 9p21.3, 6q25.1, and 2q36.3 with angiographically characterized coronary artery disease. *Atherosclerosis* 2009;205:174-180.
66. Marte T, Saely CH, Schmid F, Koch L, Drexel H. Effectiveness of atrial fibrillation as an independent predictor of death and coronary events in patients having coronary angiography. *Am J Cardiol* 2009;103:36-40.
67. Rein P, Saely CH, Aczel S, Patsch B, Drexel H. Omega-3 fatty acids significantly reduce postprandial triglyceridemia in male smokers: a pilot study. *Nutr Metab Cardiovasc Dis* 2009;19:e3-e4.
68. Saely CH, Dyballa T, Vonbank A, Woess M, Rein P, Beer S, Jankovic V, Boehnel C, Aczel S, Drexel H. Type 2 diabetes but not coronary atherosclerosis is an independent determinant of impaired mobility in angiographed coronary patients. *Diabetes Res Clin Pract* 2008;82:185-189.
69. Saely CH, Vonbank A, Rein P, Woess M, Beer S, Aczel S, Jankovic V, Boehnel C, Risch L, Drexel H. Alanine aminotransferase and gamma-glutamyl transferase are associated with the metabolic syndrome but not with angiographically determined coronary atherosclerosis. *Clin Chim Acta* 2008;397:82-86.
70. Saely CH, Muendlein A, Vonbank A, Sonderegger G, Aczel S, Rein P, Risch L, Drexel H. Type 2 diabetes significantly modulates the cardiovascular risk conferred by the PAI-1 -675 4G/5G polymorphism in angiographed coronary patients. *Clin Chim Acta* 2008;396:18-22.

71. Drexel H, Saely CH, Langer P, Loruenser G, Marte T, Risch L, Hoefle G, Aczel S. Metabolic and anti-inflammatory benefits of eccentric endurance exercise - a pilot study. *Eur J Clin Invest* 2008;38:218-226.
72. Muendlein A, Saely CH, Marte T, Schmid F, Koch L, Rein P, Langer P, Aczel S, Drexel H. Synergistic effects of the apolipoprotein E epsilon3/epsilon2/epsilon4, the cholesteryl ester transfer protein TaqIB, and the apolipoprotein C3 -482 C>T polymorphisms on their association with coronary artery disease. *Atherosclerosis* 2008;199:179-186.
73. Saely CH, Drexel H, Sourij H, Aczel S, Jahnel H, Zweiker R, Langer P, Marte T, Hoefle G, Benzer W, Wascher TC. Key role of postchallenge hyperglycemia for the presence and extent of coronary atherosclerosis: an angiographic study. *Atherosclerosis* 2008;199:317-322.
74. Drexel H, Rein P, Hostalek U, Kastelein J. Clinical Experience with prolonged-release nicotinic acid in statin-treated patients managed in the usual care setting in Austria: An analysis from NiaspnR-induced HDL-elevation for optimizing risk control (NEMO) study. *J Clinical and Basic Cardiology* 2007;10:7-10.
75. Saely CH, Rein P, Drexel H. The metabolic syndrome and risk of cardiovascular disease and diabetes: experiences with the new diagnostic criteria from the International Diabetes Federation. *Horm Metab Res* 2007;39:642-650.
76. Hoefle G, Saely CH, Risch L, Koch L, Schmid F, Rein P, Aczel S, Berchtold S, Drexel H. Relationship between the adipose-tissue hormone resistin and coronary artery disease. *Clin Chim Acta* 2007;386:1-6.
77. Hoefle G, Saely CH, Risch L, Rein P, Koch L, Schmid F, Aczel S, Marte T, Langer P, Drexel H. Leptin, leptin soluble receptor and coronary atherosclerosis. *Eur J Clin Invest* 2007;37:629-636.
78. Saely CH, Risch L, Hoefle G, Rein P, Muendlein A, Marte T, Aczel S, Langer P, Drexel H. Low serum adiponectin is independently associated with both the metabolic syndrome and angiographically determined coronary atherosclerosis. *Clin Chim Acta* 2007;383:97-102.
79. Hoefle G, Muendlein A, Saely CH, Risch L, Rein P, Koch L, Schmid F, Aczel S, Marte T, Langer P, Drexel H. The -11377 C>G promoter variant of the adiponectin gene, prevalence of coronary atherosclerosis, and incidence of vascular events in men. *Thromb Haemost* 2007;97:451-457.
80. Risch L, Saely CH, Neyer U, Hoefle G, Gouya G, Zerlauth M, Risch GM, Risch M, Drexel H. Prevalence of decreased glomerular filtration rate in patients seeking non-nephrological medical care--an evaluation using IDMS-traceable creatinine based MDRD as well as Mayo Clinic quadratic equation estimates. *Clin Chim Acta* 2007;378:71-77.
81. Risch L, Saely C, Hoefle G, Rein P, Langer P, Gouya G, Marte T, Aczel S, Drexel H. Relationship between glomerular filtration rate and the adipokines adiponectin, resistin

- and leptin in coronary patients with predominantly normal or mildly impaired renal function. *Clin Chim Acta* 2007;376:108-113.
82. Risch L, Hoefle G, Saely CH, Berchtold S, Drexel H. Evaluation of two fully automated novel enzyme-linked immunosorbent assays for the determination of human adiponectin in serum. *Clin Chim Acta* 2006;373:121-126.
  83. Saely CH, Koch L, Schmid F, Marte T, Aczel S, Langer P, Hoefle G, Drexel H. Adult Treatment Panel III 2001 but not International Diabetes Federation 2005 criteria of the metabolic syndrome predict clinical cardiovascular events in subjects who underwent coronary angiography. *Diabetes Care* 2006;29:901-907.
  84. Saely CH, Koch L, Schmid F, Marte T, Aczel S, Langer P, Hoefle G, Drexel H. Lipoprotein(a), type 2 diabetes and vascular risk in coronary patients. *Eur J Clin Invest* 2006;36:91-97.
  85. Risch L, Drexel H, Huber AR. Differences in glomerular filtration rate estimates by 2 cystatin C-based equations. *Clin Chem* 2005;51:2211-2212.
  86. Saely CH, Aczel S, Marte T, Langer P, Hoefle G, Drexel H. The metabolic syndrome, insulin resistance, and cardiovascular risk in diabetic and nondiabetic patients. *J Clin Endocrinol Metab* 2005;90:5698-5703.
  87. Hoefle G, Saely CH, Aczel S, Benzer W, Marte T, Langer P, Drexel H. Impact of total and central obesity on vascular mortality in patients undergoing coronary angiography. *Int J Obes (Lond)* 2005;29:785-791.
  88. Drexel H, Aczel S, Marte T, Benzer W, Langer P, Moll W, Saely CH. Is atherosclerosis in diabetes and impaired fasting glucose driven by elevated LDL cholesterol or by decreased HDL cholesterol? *Diabetes Care* 2005;28:101-107.
  89. Risch L, Saely CH, Reist U, Hefti M, Reist K, Huber AR. Course of glomerular filtration rate markers in patients receiving high dose glucocorticoids following subarachnoidal hemorrhage. *Clin Chim Acta* 2005; 36:205-207.
  90. Hofle G, Saely CH, Tautermann G, Aczel S, Holzmüller H, Drexel H. Relationship between various measures of bone mineral density and vertebral fractures in cardiac transplant recipients. *Swiss Med Wkly* 2004;134:215-220.
  91. Hofle G, Tautermann G, Saely CH, Drexel H. Sex-hormone-binding globulin is negatively correlated with femoral bone-mineral density in male cardiac-transplant recipients. *Wien Klin Wochenschr* 2004;116:170-175.
  92. Saely CH, Aczel S, Marte T, Langer P, Drexel H. Cardiovascular complications in Type 2 diabetes mellitus depend on the coronary angiographic state rather than on the diabetic state. *Diabetologia* 2004;47:145-146.
  93. Hofle G, Holzmüller H, Gouya G, Hergan K, Hubmann M, Langer P, Drexel H. Lower serum beta-CrossLaps in male cardiac transplant recipients treated without prednisolone. *Transpl Int* 2003;16:523-528.



94. Benzer W, Aczel S, Drexel H. A clinical practice model to estimate the cost. Effectiveness of lipid lowering therapy with statins in patients at risk for coronary artery disease. *J Clin Basic Cardiol* 2002;5:179-182.
95. Kuster GM, Amann FW, Neuenschwander C, Drexel H. High density-lipoprotein subfractions of patients using cardio-selective beta-blockers. *Cardiovasc Drugs Ther* 2002;16:127-131.
96. Geltner C, Lechleitner M, Fogar B, Ritsch A, Drexel H, Patsch JR. Insulin improves fasting and postprandial lipemia in type 2 diabetes. *Eur J Intern Med* 2002;13:256-263.
97. Drexel H, Schmid HR, Follath F. Effects of bisoprolol on lipoprotein cholesterol subfractions and apolipoproteins in patients with hypertension. *J Clin Basic Cardiol* 2001;4:57.
98. Benzer W, Fritzsche H, Kargl M, Drexel H. Revascularization of residual viable myocardium improves left ventricular dysfunction in patients after myocardial infarction. *Wien Klin Wochenschr* 1999;111:636-642.
99. Fuchs W, Wolber T, Woss E, Neyer U, Drexel H. Leptospirosis (Weil's syndrome) with renal failure, severe jaundice, disseminated hemorrhages and xanthopsia. *Schweiz Med Wochenschr* 1999;129:847-850.
100. Drexel H, Gaul GB, Grimm G, Klein W, Kleemann L, Leisch F, Mlczech J, Pichler M, Sailer S, Slany J, Steinbach K, Tragl KH, Mori M, Kuhn P. Secondary prevention following coronary intervention. Survey of 13 intervention centers in Austria *Wien Klin Wochenschr* 1999;111:643-649.
101. Benzer W, Bitschnau R, Groechnig E, Aczel S, Drexel H. Regular physical activity and risk factors for coronary heart disease. *Circulation* 1998;98:2356.
102. Ritsch A, Drexel H, Amann FW, Pfeifhofer C, Patsch JR. Deficiency of cholesteryl ester transfer protein. Description of the molecular defect and the dissociation of cholesteryl ester and triglyceride transport in plasma. *Arterioscler Thromb Vasc Biol* 1997;17:3433-3441.

## Originalarbeiten, Nephrologie

103. Sprenger-Mähr H, Zitt E, Lhotta K. Acute Kidney Injury Treated with Dialysis outside the Intensive Care Unit: A Retrospective Observational Single-Center Study. *PLoS One*. 2016 Sep 27;11(9):e0163512 PubMed PMID: 27673681; PubMed Central PMCID: PMC5038962.
104. Zitt E, Pscheidt C, Concin H, Kramar R, Lhotta K, Nagel G. Anthropometric and Metabolic Risk Factors for ESRD Are Disease-Specific: Results from a Large Population-Based Cohort Study in Austria. *PLoS One*. 2016 Aug 18;11(8):e0161376. PubMed PMID: 27537361; PubMed Central PMCID: PMC4990261.

105. Zitt E, Hafner-Giessauf H, Wimmer B, Herr A, Horn S, Friedl C, Sprenger-Mähr H, Kramar R, Rosenkranz AR, Lhotta K. Response to active hepatitis B vaccination and mortality in incident dialysis patients. *Vaccine*. 2017 Feb 1;35(5):814-820. PubMed PMID: 28049587.
106. Pronai W, Rosenkranz AR, Bock A, Klauser-Braun R, Jäger C, Pendl G, Hemetsberger M, Lhotta K. Management of secondary hyperparathyroidism: practice patterns and outcomes of cinacalcet treatment with or without active vitamin D in Austria and Switzerland - the observational TRANSIT Study. *Wien Klin Wochenschr*. 2017 PubMed PMID: 28091752.
107. Sprenger-Mähr H, Zitt E, Lhotta K. Successful Treatment of Focal Segmental Glomerulosclerosis after Kidney Transplantation with Plasma Exchange and Abatacept in a Patient with Juvenile Rheumatoid Arthritis, *Case Rep Transplant* 2016;2016:7137584. doi: 10.1155/2016/7137584
108. Zitt E, Lhotta K. Management of secondary hyperparathyroidism-current impact of parathyroidectomy, *Wien Med Wochenschr* 2016 May;166(7-8):254-8. doi: 10.1007/s10354-016-0444-3
109. Raffler G, Zitt E, Sprenger-Mähr H, Nagel M, Lhotta K. Autosomal dominant tubulointerstitial kidney disease caused by uromodulin mutations: seek and you will find, *Wien Klin Wochenschrift* 2016 Apr;128(7-8):291-4. doi: 10.1007/s00508-015-0948-7
110. Pscheidt C, Nagel G, Zitt E, Kramar R, Concin H, Lhotta K. Sex- and Time-Dependent Patterns in Risk Factors of End-Stage Renal Disease: A Large Austrian Cohort with up to 20 Years of Follow-Up, *Plos one* 2015 Aug 31;10(8):e0135052. doi: 10.1371
111. Zitt E, Sprenger-Mähr H, Mündle M, Lhotta K. Efficacy and safety of body weight-adapted oral cholecalciferol substitution in dialysis patients with vitamin D deficiency, *BMC Nephrology*, 2015 Aug 4;16(28), doi: 10.1186/s12882-015-0116-3
112. Valentiny C, Dierschmid H, Lhotta K. Streptococcus uberis and staphylococcus aureus forefoot and blood stream co-infection in a hemodialysis patient: a case report, *BMC Nephrology*, 2015 May 28;16(73), doi: 10.1186/s12882-015-0069-6
113. Stanic M, Meusburger E, Hartmann G, Lhotta K. Hafnia alvei urosepsis in a kidney transplant patient *Case Rep Transplant* 2015 April, doi.org/10.1155/2015/863131
114. Ender M, Cejna M, Lhotta K. End-stage renal disease from renal metastases, *Kidney International* 2014, 87(246), doi:10.1038/ki.2014.140
115. Kronbichler A, Frank R, Kirschfink M, Szilagy A, Csuka D, Prohaszka Z, Schratzberger P, Lhotta K. Efficacy of eculizumab in a patient with immunoabsorption-dependent catastrophic antiphospholipid syndrome: a case report, *Medicine* 2014, 93(26):e143., doi: 10.1097/MD.000000000000143.
116. Zitt E, Sturm G, Kroneneberg F, Neyer U, Knoll F, Lhotta K, Weiss G. Iron supplementation and mortality in incident dialysis patients: an observational study, *Plos One* 2014 Dec 2;9(12):e114144. doi: 10.1371/journal.pone.01141442014

117. Zitt E, Knoll F, Lhotta K. Variable mechanisms of vascular calcification in different segments of the arterial tree in patients with chronic kidney disease, *Kidney Int.* 2014 Oct;86(4):858. doi: 10.1038/ki.2014.183.
118. Jennings P, Crean D, Aschauer L, Limonciel A, Moenks K, Kern G, Hewitt P, Lhotta K, Lukas A, Wilmes A, Leonard MO. Interleukin-19 as a translational indicator of renal injury. *Arch Toxicol.* 2015 Jan;89(1):101-6. doi: 10.1007/s00204-014-1237-3
119. Kerschbaum J, Vychytil A, Lhotta K, Prischl F, Wiesholzer M, Machhold-Fabrizii V, Kopriva-Altfahrt G, Schwarz C, Balcke P, Oberbauer R, Kramar R, König P, Rudnicki M. Treatment with oral vitamin D is associated with decreased risk of peritonitis and improved survival in patients on peritoneal dialysis, *PLoS One.* 2013 Jul 2;8(7):e67836. doi: 10.1371/journal.pone.0067836.
120. Risch L, Lhotta K, Meier D, Medina-Escobar P, Nydegger U, Risch M., The Serum uromodulin Level is associated with kidney function. *Clin Chem Lab Med.* 2014 Dec;52(12):1755-61. doi: 10.1515/cclm-2014-0505.
121. Nagel G, Zitt E, Peter R, Pompelle A, Concin H, Lhotta K. Body mass index and metabolic factors predict glomerular filtration rate and albuminuria over 20 years in a high-risk population, *BMC Nephrol.* 2013 Aug 20;14:177. doi: 10.1186/1471-2369-14-177
122. Moskowitz J, Piret S, Lhotta K, Kitzler T, Tashman A, Velez E, Thakker R, Kotanko P. Association between genotype and phenotype in uromodulin-associated kidney Disease, *Clin J Am Soc Nephrol.* 2013 Aug;8(8):1349-57. doi: 10.2215/CJN.11151012.
123. Meusbürger E, Mündlein A, Zitt E, Obermayer-Pietsch B, Kotzot D, Lhotta K, Medullary nephrocalcinosis in an adult patient with idiopathic infantile hypercalcemia and a novel CYP24A1 mutation, *Clin Kidney J.* 2013 Apr;6(2):211-215., DOI: 10.1093/ckj/sft008
124. Zitt E, König M, Vychytil A, Auinger M, Wallner M, Gingenhel G, Schilcher G, Rudnicki M, Salmhofer H, Lhotta K., Use of sodium thiosulphate in a multi-interventional setting for the treatment of calciphylaxis in dialysis patients, *Nephrol Dial Transplant.* 2013 May;28(5):1232-40. doi: 10.1093/ndt/gfs548.
125. Lhotta K. Bedeutung der Prädialysevorbereitung und Patienteninformation für die Wahl des Dialyseverfahrens, *Wien Med. Wochenschrift;* 2013 June; 163 (11);266-270; DOI 10.1007/s10354-013-0192-6, 2013
126. Knoll F, Zitt E, Intemann D, Lhotta K. Juvenile elastic arteries after 28 years of renal replacement therapy in a patient with complete complement C4 deficiency, *BMC Nephrology* 2012 Dec 2;13:161. doi: 10.1186/1471-2369-13-161
127. Lhotta K, Piret SE, Kramar R, Thakker RV, Sunder-Plassman G, Kotanko P. Epidemiology of uromodulin-associated kidney disease-results from a nation-wide survey, *Nephron Extra* 2012 Jan 2(1):147-58, doi: 10.1159/000339102

128. Zitt E, Sprenger-Mähr H, Knoll F, Neyer U, Lhotta K. Vitamin D deficiency is associated with poor response to active hepatitis B immunisation in patients with chronic kidney disease, *Vaccine*. 2012 Jan 20;30(5):931-5; doi: 10.1016/j.vaccine.2011.11.086
129. Zitt E, Lamina C, Sturm G, Knoll F, Lins F, Freistätter O, Kronenberg F, Lhotta K, Neyer U. Interaction of time-varying albumin and phosphorus on mortality in incident dialysis patients, *Clin J Am Soc Nephrol*. 2011 Nov;6(11):2650-6. doi: 10.2215/CJN.03780411.
130. Zitt E, Woess E, Mayer G, Lhotta K. Effect of cinacalcet on renal electrolyte handling and systemic arterial blood pressure in kidney transplant patients with persistent hyperparathyroidism, *Transplantation*. 2011 Oct 27;92(8):883-9. doi: 10.1097/TP.0b013e31822d87e8.
131. Knoll F, Sturm G, Lamina C, Zitt E, Lins F, Freistätter O, Kronenberg F, Lhotta K, Neyer U. Coumarins and survival in incident dialysis patients. *Nephrol Dial Transplant*. 2012 Jan;27(1):332-7. doi: 10.1093/ndt/gfr341
132. Sturm G, Lamina C, Zitt E, Lhotta K, Haider F, Neyer U, Kronenberg F. Association of HbA1c values with mortality and cardiovascular events in diabetic dialysis patients. The INVOR study and review of the literature, *PLoS One*. 2011;6(5):e20093. doi: 0.1371/journal.pone.0020093.
133. Koch LD, Knoll F, Hartmann G, Lhotta K. Recurrent exit-site infection due to *Staphylococcus lugdunensis*--a virulent coagulase-negative *Staphylococcus*. *Perit Dial Int*. 2011 May-Jun;31(3):372-3. doi: 10.3747/pdi.2010.00272.
134. Gouya G, Sturm G, Lamina C, Zitt E, Freistätter O, Struck J, Wolzt M, Knoll F, Lins F, Lhotta K, Neyer U, Kronenberg F. The association of mid-regional pro-adrenomedullin and mid-regional pro-atrial natriuretic peptide with mortality in an incident dialysis cohort. *PLoS One*. 2011 Mar 7;6(3):e17803. doi: 10.1371/journal.pone.0017803.
135. Häring N, Mähr HS, Mündle M, Strohal R, Lhotta K. Early detection of renal damage caused by fumaric acid ester therapy by determination of urinary  $\beta$ 2-microglobulin. *Br J Dermatol*. 2011 Mar;164(3):648-51. doi: 10.1111/j.1365-2133.2010.10171.x.
136. Sturm G, Lamina C, Zitt E, Lhotta K, Lins F, Freistätter O, Neyer U, Kronenberg F. Sex-specific association of time-varying haemoglobin values with mortality in incident dialysis patients. *Nephrol Dial Transplant*. 2010 Aug;25(8):2715-22. doi: 10.1093/ndt/gfq101
137. Lhotta K, Neuweiler J, Mark W, Wöss E. Sirolimus-associated acute interstitial nephritis in a renal allograft, *Transpl Int*. 2010 Jun;23(6):e22-3. doi: 10.1111/j.1432-2277.2009.01016.x.

## Originalarbeiten, Onkologie

138. Muendlein A, Rohde BH, Gasser K, Haid A, Rauch S, Kinz E, Drexel H, Hofmann W, Schindler V, Kapoor R, Decker T, Lang AH. Evaluation of BRCA1/2 mutational status among German

- and Austrian women with triple-negative breast cancer. *J Canc Res Clin Oncol* 2015; 141: 2005-2012.
139. Kinz E, Leiherer A, Lang AH, Drexel H, Muendlein A. (2014) Accurate quantitation of JAK2 V617F allele burden by array-based digital PCR. *Int J Lab Hematol* 2015; 37: 217-24.
140. Muendlein M, Hubalek M, Geller-Rhomberg S, Gasser K, Winder T, Drexel H, Decker T, Müller-Holzner E, Chamson M, Marth C, Lang AH. Significant survival impact of MACC1 polymorphisms in HER2 positive breast cancer patients *Eur J Canc* 2014; 50: 2134 - 2141.
141. Lang AH, Drexel H, Geller-Rhomberg S, Stark N, Winder T, Geiger K, Muendlein A. Optimized allele-specific real-time PCR assays for the detection of common mutations in KRAS and BRAF. *J Mol Diagn* 2011;13:23-28.
142. Winder T, Schuster A, Becherer A et al. Advanced inoperable type B3 thymoma: monitoring of a novel therapeutic approach with radio-chemotherapy and sorafenib by FDG-PET and CT. *Nuklearmedizin* 2010;49:N41-N43.
143. Winder T, Muendlein A, Gasser K, Lingg G, Walser J, Karner-Hanusch J, Dirschmid K, Drexel H, Lang A. Challenges and pitfalls in HNPCC: A pedigree of an austrian HNPCC family beyond four generations! *Mag Europ Med Oncol* 2009;2:41-44.
144. Winder T, Muendlein A, Rhomberg S, Dirschmid K, Hartmann B, Knauer M, Drexel H, Wenzl E, de Vries A, Lang A. Different types of K-Ras mutations are conversely associated with overall survival in patients with colorectal cancer. *Oncol Rep* 2009;21:1283-1287.
145. Lang AH, Geller-Rhomberg S, Winder T, Stark N, Gasser K, Hartmann B, Kohler B, Grizelj I, Drexel H, Muendlein A. A common variant of the MACC1 gene is significantly associated with overall survival in colorectal cancer patients. *BMC Cancer* 2012;12:20.
146. Muendlein A, Lang AH, Geller-Rhomberg S, Winder T, Gasser K, Drexel H, Decker T, Mueller-Holzner E, Chamson M, Marth C, Hubalek M. Association of a common genetic variant of the IGF-1 gene with event-free survival in patients with HER2-positive breast cancer. *J Cancer Res Clin Oncol* 2013; 139: 491-498.

## Originalarbeiten, Weitere Forschungsgebiete

147. Huegel R, Muendlein A, Volbeding L, Drexel H, Richtig E, Wehkamp U, Painsi C, Lange-Asschenfeldt B, Hausschild A, Egberts F. Serum levels of hepatocyte growth factor as a potential tumor marker in patients with malignant melanoma. *Melanoma Res.* 2016 Aug;26(4):354-60
148. Biebl A, Muendlein A, Kinz E, Drexel H, Kabesch M, Zenz W, Elling R, Müller C, Keil T, Lau S, Simma B. Confirmation of Host Genetic Determinants in the CFH Region and Susceptibility to Meningococcal Disease in a Central-European Study Sample. *Pediatr Infect Dis J.* 2015; 34: 1115-1117.

149. DeVries AF, Piringer G, Kremser C, Judmaier W, Saely CH, Lukas P, Ofner D. Pretreatment evaluation of microcirculation by dynamic contrast-enhanced magnetic resonance imaging predicts survival in primary rectal cancer patients. *Int J Radiat Oncol Biol Phys* 2014; 90: 1161-1167.
150. Biebl A, Muendlein A, Kazakbaeva Z, Heuberger S, Sonderegger G, Drexel H, Lau S, Nickel R, Kabesch, M, Simma B. CD14 C-159T and toll-like receptor 4 Asp299Gly polymorphisms in surviving meningococcal disease patients. *PLoS One* 2009;4:e7374.
151. Rhomberg W, Eiter H, Schmid F, Saely CH. Combined Vindesine and Razoxane Shows Antimetastatic Activity in Advanced Soft Tissue Sarcomas. *Clin Exp Metastasis* 2008; 75-80.
152. Rhomberg W, Eiter H, Schmid F, Saely CH. Razoxane and Vindesine in Advanced Soft Tissue Sarcomas: Impact on Metastasis, Survival and Radiation Response. *Anticancer Res* 2007; 27: 3609-3614.
153. Gouya G, Hartmann G, Fae P, Teuber M, Holzmueller H, Benzer W, Lang A, Schuster A, Drexel H. A case of fulminant post-transplant lymphoproliferative disorder and septicemia. *Clin Transplant* 2006;20:261-264.
154. Zuber-Jerger I, Drexel H. Aphthous colitis induced by non-steroidal antirheumatic drugs. *Swiss Med Wkly* 2003;133:544-545.
155. Wiederin TBJ, Krings T, Vonbank H, Hergan K, Peschina W, Fritsche H, Mathies R, Drexel H, Koppi S. MRI, proton magnetic resonance spectroscopy and Tcc-99m HMPAO SPECT in a patient with transient global amnesia. *Neuroradiol* 2001;11:216-220.
156. Tautermann G, Ruebsamen H, Beck M, Dertinger S, Drexel H, Lohse P. R116C mutation of cationic trypsinogen in a Turkish family with recurrent pancreatitis illustrates genetic microheterogeneity of hereditary pancreatitis. *Digestion* 2001;64:226-232.
157. Dertinger S, Dirschmid K, Vogel W, Drexel H. Immunosuppressive therapy for carbamazepine-induced hypersensitivity syndrome and hepatitis. *J Hepatol* 1998;28:356-357.

## Reviews

158. Saely CH, Drexel H. Impact of diet and exercise on proprotein convertase subtilisin/kexin 9: A mini-review. *Vascul Pharmacol*. 2016 Dec;87:10-13. PMID: 27746375
159. Leihner A, Muendlein A, Drexel H. Phytochemicals and their impact on adipose tissue inflammation and diabetes. *Vascul Pharmacol* 2013; 58:3-20
160. Saely CH, Geiger K, Drexel H. Brown versus white adipose tissue: a mini-review. *Gerontology* 2012;58:15-23

161. Saely CH, Drexel H, Huber K. High-dose statin therapy for high-risk patients. *Herz* 2010;35:497-502. PMID: 20941469
162. Fraunberger P, Drexel H, Walli AK. Pathophysiology of sepsis and possible influence of statins. *Dtsch Med Wochenschr* 2010;135:2128-2132. PMID: 20960384
163. Winder, T, Lang, A, und Mündlein A (2011) Molekulare Diagnostik am Beispiel des kolorektalen Karzinoms, *Tumordiagnostik und Therapie* 32: 66-69
164. Mündlein A, Winder T, Loacker S, Drexel H. Einfluss von DNA-Variationen auf die koronare Herzerkrankung. *J Kardiologie* 2008;11-12:342-346.
165. Mündlein A, Geller-Rhomberg S, Stark N, Drexel H. Genetischer Hintergrund des (Nicht-) Ansprechens auf eine Lipidogrel-Therapie. *J Kardiologie* 2011;18:312-319
166. Saely CH, Drexel V, Vonbank A, Drexel H. Lipid management in Type-2-Diabetes: the case for combination therapy? *Therapy* 2011; 8:129-141.

## Guidelines, Position Papers, Recommendations

167. Vonbank A, Agewall S, Kjeldsen KP, Lewis BS, Torp-Pedersen C, Ceconi C, Funck-Brentano C, Kaski JC, Niessner A, Tamargo J, Walther T, Wassmann S, Rosano G, Schmidt H, Saely CH, Drexel H. Comprehensive efforts to increase adherence to statin therapy. *Eur Heart J*. 2017 PMID: 28077470
168. Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, Hoes AW, Jennings CS, Landmesser U, Pedersen TR, Reiner Ž, Riccardi G, Taskinen MR, Tokgozoglu L, Verschuren WM, Vlachopoulos C, Wood DA, Zamorano JL. [2016 ESC/EAS Guidelines for the Management of Dyslipidaemias]. *Kardiologie Pol.* 2016;74(11):1234-1318. PMID: 27910077
169. Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, Hoes AW, Jennings CS, Landmesser U, Pedersen TR, Reiner Ž, Riccardi G, Taskinen MR, Tokgozoglu L, Verschuren WM, Vlachopoulos C, Wood DA, Zamorano JL. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). *Atherosclerosis*. 2016 Oct;253:281-344. PMID: 27594540
170. Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, Hoes AW, Jennings CS, Landmesser U, Pedersen TR, Reiner Ž, Riccardi G, Taskinen MR, Tokgozoglu L, Verschuren WM, Vlachopoulos C, Wood DA, Zamorano JL; Authors/Task Force Members 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. *Eur Heart J*. 2016 Oct 14;37(39):2999-3058. PMID: 27567407
171. Niessner A, Tamargo J, Morais J, Koller L, Wassmann S, Husted ST, Torp-Pedersen C, Kjeldsen K, Lewis BS, Drexel H, Kaski JC, Atar D, Storey RF, Lip GYH, Verheugt FWH, Agewall

- S. Reversal strategies for Non-vitamin K oral anticoagulants – a critical appraisal of available evidence and recommendations for the clinical management. *Eur H J* 2015, epub ahead of print
172. Rosano GM, Lewis B, Agewall S, Wassmann S, Vitale C, Schmidt H, Drexel H, Patak A, Torp-Pedersen C, Kjeldsen KP, Tamargo J. Gender differences in the effect of cardiovascular drugs: a position document of the Working Group on Pharmacology and Drug Therapy of the ESC; *Eur Heart J* 2015; 36: 2677-2680.
173. Drexel H, Vonbank A, Fraunberger P, Riesen WF, Saely CH. Toward a more professional and practical medical education: a novel Central European approach. *Adv Med Edu Pract* 2015; 6: 1-9.
174. Clodi M, Abrahamian H, Drexel H, Fasching P, Hoppichler F, Kautzky-Willer A, Lechleitner M, Ludvik B, Prager R, Roden M, Saely CH, Schernthaner G, Schober E, Toplak H, Wascher T, Weitgasser R. Antihyperglycemic Treatment Guidelines for diabetes mellitus type 2. *Wien Klin Wochenschr* 2012; 124, Suppl 2: 10-16.
175. Schernthaner G, Drexel H, Rosenkranz AR, Schernthaner GH, Watschinger B. Antihypertensive therapy in diabetes mellitus: 2012 guidelines of the Austrian diabetes association. *Wien Klin Wochenschr* 2012; 124, Suppl 2: 23-27.
176. Saely CH, Drexel H. Lipid therapy in patients with diabetes. *Wien Med Wochenschr* 2010;160:25-29. PMID: 20229158.
177. Drexel H. Statins, fibrates, nicotinic acid, cholesterol absorption inhibitors, anion-exchange resins, omega-3 fatty acids: which drugs for which patients? *Fundam Clin Pharmacol* 2009;23:687-692.
178. Drexel H. Nicotinic acid in the treatment of hyperlipidaemia. *Fundam Clin Pharmacol* 2007;21 Suppl 2:5-6.
179. Drexel H. Reducing risk by raising HDL-cholesterol: the evidence. *Eur Heart J* 2006;8:F23-F29.
180. Sheperd J, Betteridge J, Van Gaal L on behalf of a European Consensus Panel. Nicotinic acid in the management of dyslipidaemia associated with diabetes and metabolic syndrome: a position paper developed by a European Consensus Panel. *Curr Med Res Opin* 2005;21:665-682.
181. Drexel H. Modern intervention strategies for managing dyslipidaemia: the case for combination therapy. *Br J Diabetes Vasc Dis* 2005;5:S17-S23.
182. Lechleitner M, Drexel H. Diabetes and lipids. *Wien Med Wochenschr* 2003;153:469-473.



## Letters

183. Muendlein A, Ebner J, Zitt E. Prevalence of the Janus Kinase 2 V617F Mutation in Patients with End-Stage Renal Disease. *Nephron*. 2016 Nov 26. PMID: 27889755
184. Saely CH, Drexel V, Drexel H. The fate of fat: A response. *Gerontology* 2011; 58: 123-125.
185. Saely CH, Rein P, Drexel H. Combination lipid therapy in type 2 diabetes. *N Engl J Med* 2010;363:692
186. Winder T, Scheithauer W, Lang A. Comment on Karapetis et al. K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer. *N Engl. J Med* 2009; 360: 834-835.
187. Saely CH, Marte T, Drexel H. Lp(a) lipoprotein, vascular disease, and mortality in the elderly. *N Engl J Med* 2004;350:1150-1152
188. Risch L, Drexel H, Huber AR. Cystatin C and the risk of death. *N Engl J Med* 2005;353:842-844.
189. Hoefle G, Holzmueller H, Drexel H. Alendronate versus calcitriol for prevention of bone loss after cardiac transplantation. *N Engl J Med* 2004;350:2306-2308.
190. Hofle G, Holzmueller H, Drexel H. Bisphosphonates routine in prevention of post-transplant osteoporosis? *J Bone Miner Res* 2005;20:1482.

## Pharma-Studien

191. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE, EMPA-REG OUTCOME Investigators. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. *NEJM* 2015; 373: 2117-2128.
192. Aschner P, Katzeff HL, Guo H, Sunga S, Williams-Herman D, Kaufman KD, Goldstein BJ; Sitagliptin Study 049 Group. Efficacy and safety of monotherapy of sitagliptin compared with metformin
193. Pokorney SD, Piccini JP, Stevens SR, Patel MR, Pieper KS, Halperin JL, Breithardt G, Singer DE, Hankey GJ, Hacke W, Becker RC, Berkowitz SD, Nessel CC, Mahaffey KW, Fox KA, Califf RM; ROCKET AF Steering Committee & Investigators.; ROCKET AF Steering Committee Investigators.. Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF. *J Am Heart Assoc*. 2016 Mar 8;5(3):e002197. doi: 10.1161/JAHA.115.002197. PubMed PMID: 26955859; PubMed Central PMCID: PMC4943233.
194. Moriarty PM, Thompson PD, Cannon CP, Guyton JR, Bergeron J, Zieve FJ, Bruckert E, Jacobson TA, Kopecky SL, Baccara-Dinet MT, Du Y, Pordy R, Gipe DA; ODYSSEY ALTERNATIVE Investigators.. Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients,

- with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial. *J Clin Lipidol*. 2015 Nov-Dec;9(6):758-69. doi: 10.1016/j.jacl.2015.08.006. PubMed PMID: 26687696.
195. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius H, Lewis BS, Ophuis TO, Jukema JW, De Ferrari GM, Ruzyllo W, De Lucca P, Im K, Bohula EA, Reist C, Wiviott SD, Tershakovec AM, Musliner TA, Braunwald E, Califf RM; IMPROVE-IT Investigators.. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. *N Engl J Med*. 2015 Jun 18;372(25):2387-97. doi: 10.1056/NEJMoa1410489. PubMed PMID: 26039521.
196. Lip GY, Rushton-Smith SK, Goldhaber SZ, Fitzmaurice DA, Mantovani LG, Goto S, Haas S, Bassand JP, Camm AJ, Ambrosio G, Janský P, Al Mahmeed W, Oh S, vanEickels M, Raatikainen P, Steffel J, Oto A, Kayani G, Accetta G, Kakkar AK; GARFIELD-AF Investigators.. Does sex affect anticoagulant use for stroke prevention in nonvalvular atrial fibrillation? The prospective global anticoagulant registry in the FIELD-Atrial Fibrillation. *Circ Cardiovasc Qual Outcomes*. 2015 Mar;8(2 Suppl 1):S12-20. doi: 10.1161/CIRCOUTCOMES.114.001556. PubMed PMID: 25714828.
197. Halperin JL, Hankey GJ, Wojdyla DM, Piccini JP, Lokhnygina Y, Patel MR, Breithardt G, Singer DE, Becker RC, Hacke W, Paolini JF, Nessel CC, Mahaffey KW, Califf RM, Fox KA; ROCKET AF Steering Committee and Investigators.. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). *Circulation*. 2014 Jul 8;130(2):138-46. doi: 10.1161/CIRCULATIONAHA.113.005008. PubMed PMID: 24895454.
198. Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, Chaitman BR, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJ, Mundl H, Nicholls SJ, Shah PK, Tardif JC, Wright RS; dal-OUTCOMES Investigators.. Effects of dalcetrapib in patients with a recent acute coronary syndrome. *N Engl J Med*. 2012 Nov 29;367(22):2089-99. doi: 10.1056/NEJMoa1206797. PubMed PMID: 23126252.
199. Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Persson F, Desai AS, Nicolaidis M, Richard A, Xiang Z, Brunel P, Pfeffer MA; ALTITUDE Investigators.. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. *N Engl J Med*. 2012 Dec 6;367(23):2204-13. doi: 10.1056/NEJMoa1208799. PubMed PMID: 23121378.
200. ORIGIN Trial Investigators., Gerstein HC, Bosch J, Dagenais GR, Díaz R, Jung H, Maggioni AP, Pogue J, Probstfield J, Ramachandran A, Riddle MC, Rydén LE, Yusuf S. Basal insulin and cardiovascular and other outcomes in dysglycemia. *N Engl J Med*. 2012 Jul 26;367(4):319-28. doi: 10.1056/NEJMoa1203858. PubMed PMID: 22686416.
201. ORIGIN Trial Investigators., Bosch J, Gerstein HC, Dagenais GR, Díaz R, Dyal L, Jung H, Maggioni AP, Probstfield J, Ramachandran A, Riddle MC, Rydén LE, Yusuf S. n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. *N Engl J Med*. 2012 Jul 26;367(4):309-18. doi: 10.1056/NEJMoa1203859. PubMed PMID: 22686415.

202. EINSTEIN–PE Investigators., Büller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF, Minar E, Chlumsky J, Verhamme P, Wells P, Agnelli G, Cohen A, Berkowitz SD, Bounameaux H, Davidson BL, Misselwitz F, Gallus AS, Raskob GE, Schellong S, Segers A. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. *N Engl J Med.* 2012 Apr 5;366(14):1287-97. doi: 10.1056/NEJMoa1113572. PubMed PMID: 22449293.
203. Morrow DA, Braunwald E, Bonaca MP, Ameriso SF, Dalby AJ, Fish MP, Fox KA, Lipka LJ, Liu X, Nicolau JC, Ophuis AJ, Paolasso E, Scirica BM, Spinar J, Theroux P, Wiviott SD, Strony J, Murphy SA; TRA 2P–TIMI 50 Steering Committee and Investigators.. Vorapaxar in the secondary prevention of atherothrombotic events. *N Engl J Med.* 2012 Apr 2;366(15):1404-13. doi: 10.1056/NEJMoa1200933. PubMed PMID: 22443427.
204. Hankey GJ, Patel MR, Stevens SR, Becker RC, Breithardt G, Carolei A, Diener HC, Donnan GA, Halperin JL, Mahaffey KW, Mas JL, Massaro A, Norrving B, Nessel CC, Paolini JF, Roine RO, Singer DE, Wong L, Califf RM, Fox KA, Hacke W; ROCKET AF Steering Committee investigators.. Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. *Lancet Neurol.* 2012 Apr;11(4):315-22. doi: 10.1016/S1474-4422(12)70042-X. PubMed PMID: 22402056.
205. Lüscher TF, Taddei S, Kaski JC, Jukema JW, Kallend D, Münzel T, Kastelein JJ, Deanfield JE; dal-VESSEL Investigators.. Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial. *Eur Heart J.* 2012 Apr;33(7):857-65. doi: 10.1093/eurheartj/ehs019. PubMed PMID: 22345126; PubMed Central PMCID: PMC3345558.
206. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM; ROCKET AF Investigators.. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. *N Engl J Med.* 2011 Sep 8;365(10):883-91. doi: 10.1056/NEJMoa1009638. PubMed PMID: 21830957.
207. Alexander JH, Lopes RD, James S, Kilaru R, He Y, Mohan P, Bhatt DL, Goodman S, Verheugt FW, Flather M, Huber K, Liaw D, Husted SE, Lopez-Sendon J, De Caterina R, Jansky P, Darius H, Vinereanu D, Cornel JH, Cools F, Atar D, Leiva-Pons JL, Keltai M, Ogawa H, Pais P, Parkhomenko A, Ruzyllo W, Diaz R, White H, Ruda M, Geraldles M, Lawrence J, Harrington RA, Wallentin L; APPRAISE-2 Investigators.. Apixaban with antiplatelet therapy after acute coronary syndrome. *N Engl J Med.* 2011 Aug 25;365(8):699-708. doi: 10.1056/NEJMoa1105819. PubMed PMID: 21780946.
208. Schwartz GG, Olsson AG, Ballantyne CM, Barter PJ, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJ, Shah PK, Tardif JC, Chaitman BR, Duttlinger-Maddux R, Mathieson J; dal-OUTCOMES Committees and Investigators. Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute

- coronary syndrome. *Am Heart J.* 2009 Dec;158(6):896-901.e3. doi: 10.1016/j.ahj.2009.09.017. PubMed PMID: 19958854.
209. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA; PLATO Investigators., Freij A, Thorsén M. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. *N Engl J Med.* 2009 Sep 10;361(11):1045-57. doi: 10.1056/NEJMoa0904327. PubMed PMID: 19717846.
210. APPRAISE Steering Committee and Investigators., Alexander JH, Becker RC, Bhatt DL, Cools F, Crea F, Dellborg M, Fox KA, Goodman SG, Harrington RA, Huber K, Husted S, Lewis BS, Lopez-Sendon J, Mohan P, Montalescot G, Ruda M, Ruzyllo W, Verheugt F, Wallentin L. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. *Circulation.* 2009 Jun 9;119(22):2877-85. doi: 10.1161/CIRCULATIONAHA.108.832139. PubMed PMID: 19470889.
211. Brugts JJ, de Maat MP, Boersma E, Witteman JC, van Duijn C, Uitterlinden AG, Bertrand M, Remme W, Fox K, Ferrari R, Danser AH, Simoons ML; EUROPA-PERGENE investigators.. The rationale and design of the PERindopril GENetic association study (PERGENE): a pharmacogenetic analysis of angiotensin-converting enzyme inhibitor therapy in patients with stable coronary artery disease. *Cardiovasc Drugs Ther.* 2009 Apr;23(2):171-81. doi: 10.1007/s10557-008-6156-1. PubMed PMID: 19082699.
212. Erdmann E, Charbonnel B, Wilcox RG, Skene AM, Massi-Benedetti M, Yates J, Tan M, Spanheimer R, Standl E, Dormandy JA; PROactive Investigators.. Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08). *Diabetes Care.* 2007 Nov;30(11):2773-8. PubMed PMID: 17666462.
213. Erdmann E, Dormandy JA, Charbonnel B, Massi-Benedetti M, Moules IK, Skene AM; PROactive Investigators.. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study. *J Am Coll Cardiol.* 2007 May 1;49(17):1772-80. PubMed PMID: 17466227.
214. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefèbvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Korányi L, Laakso M, Mokán M, Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, Schernthaner G, Schmitz O, Skrha J, Smith U, Taton J; PROactive Investigators.. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomized controlled trial. *Lancet.* 2005 Oct 8;366(9493):1279-89. PubMed PMID: 16214598.

## Weitere Artikel

215. Saely CH, Drexel H. The Periscope study. *J Kardiol* 2008;15:255-257.
216. Drexel H. The role of hyperlipidaemia in peripheral arterial occlusive disease. *J Kardiol* 2003;10:146-148.
217. Huber K, Baumgartner H, Darius H, Drexel H, Grimm M, Lang I, Metzler H, Mulac K, Pichler M, Watzke H, Weidinger F, Weihs W, Weltermann A, Wojta J, Zenker G, Christ G. Der Einsatz von Clopidogrel bei Patienten mit akutem Koronarsyndromen, nach perkutaner koronarer Intervention und Stentimplantation. *J Kardiol* 2006;13:168-174.
218. Drexel H. Neue Argumente und Strategien zur Behandlung des HDL-Cholesterins. *J Kardiol* 2005;12:12-14.
219. Drexel H. Ezetrol: Die Fakten. *J Kardiol* 2005;12:9-10.
220. Aczel S, Marte T, Drexel H. Modulation der Blutfette durch körperliche Bewegung. *J Kardiol* 2004;11:399-402.
221. Marte T, Drexel H. Lipidsenker bei Hypertonie - Was besagt die Evidenz? *J Hypertonie* 2004;8:7-10.
222. Drexel H. Niedriges HDL: ein koronarer Risikofaktor? *J Kardiol* 2004;11:5-6.
223. Drexel H. Hohes HDL schützt vor Atherosklerose. *Med Trib* 2004;50:12.
224. Drexel H, Marte T. Gemeinsame Präventionsstrategien bei Herzinfarkt und Schlaganfall? *Panvascular* 2003;4:6-9.
225. Saely CH, Drexel H. Bewährte und neue Präventionsziele bei kardiovaskulären Erkrankungen. *Wien Med Wochenschr* 2012;1:31.
226. Drexel H, Saely CH. Glitazone - Was jeder Kardiologe wissen sollte. *Wien Med Wochenschr* 2011;1:14-16.
227. Saely CH, Drexel H. Highlights - kardiovaskuläre Prävention. *Wien Med Wochenschr* 2009;7:14-16.
228. Drexel H, Saely CH. Lifestyle versus Medikamente. *Wien Med Wochenschr* 2009;7:20-22.
229. Drexel H, Saely CH. Fettgewebe - diabetische Dyslipidämie als Schnittpunkt zur Atherosklerose. *Wien Med Wochenschr* 2009;12:10-12. PMID: 20229158
230. Drexel H. Dyslipidämie als Schnittstelle zur Atherosklerose. *Wien Klin Wochenschr* 2009;21-22:4.
231. Toplak H, Drexel H, Hoppichler F, Huber K, Ludvik B. Hochdosis-Statintherapie versus zaghafte Lipidintervention. *J Vask Med* 2008;2:19-21.

232. Saely CH. Kongressbericht: Top Cardiologists' Meeting zum Thema „Therapieresistente arterielle Hypertonie: Renale Sympathikusdenervation“ J. Kardiol. 2012.; 19 (11-12): 348-350
233. Risch L, Saely CH, Drexel H. The medical laboratory in preventive care. Ther Umsch 2008;65:481-485. PMID: 18791961
234. Saely CH, Drexel V, Drexel H. Herzinsuffizienz und Diabetes. Wien Med Wochenschr 2012;8:13-16.
235. Bochdanky T, Boeckelberger M, Leube W, Solti K, Drexel H. Evaluation zweier interdisziplinärer Nachsorgestationen. Phys Med Rehab Kuror 2009;19:256-265.
236. Fraunberger P., Drexel H., Walli A.K., Pathophysiologie der Sepsis und deren mögliche Beeinflussung durch HMG-CoA-Reduktase-Inhibitoren, Deutsche Medizinische Wochenschrift, 2010; 135: 2128-2132 (Sonderdruck Thieme-Verlag)
237. Saely CH, Drexel, H. Bedeutung der Lipidtherapie bei Diabetes. Wiener Medizinische Wochenschrift, 2010; 1-2: 25-29.
238. Drexel H, Saely CH. Optimale Lipid-Therapie 2010. Wiener Medizinische Wochenschrift (Kongressjournal), 2010; 2:19-22.
239. Saely CH, Drexel H. Management der Herzinsuffizienz aus diabetologischer Sicht. Diabetes Forum 2010; 1: 24-30.
240. Saely CH, Drexel H. Adipositas: Risikofaktor für Diabetes und koronare Herzerkrankung. Jatro Diabetes & Stoffwechsel 2010; 2:28-31.
241. Saely CH, Drexel H. Diabetes und Herzinsuffizienz: Komorbidität vermeiden. Ärzte Krone 2010; 10: 10-14.
242. Saely CH, Drexel H. Adipositas: Risikofaktor für Diabetes und koronare Herzerkrankung. Jatro Kardiologie & Gefäßmedizin 2010; 2:8-10.
243. Drexel H, Saely CH. Lipide, CRP und Vascular Remodelling. Wiener Medizinische Wochenschrift (Kongressjournal) 2010; 6: 25-26.
244. Drexel H, Saely CH. Viele Wege führen zum Ziel – Optimale Lipidtherapie 2010. Universum Innere Medizin 2010; 6: 45-47.
245. Drexel H. Update vom Kardiologiekongress: Abwärtsgehen ist gut für die Herzgesundheit. Ärzte Krone 2010; 17: 52.
246. Saely CH. Kongressbereich: Top Cardiologist's Meeting zum Thema „Atherosklerose und Inflammation“. J Kardiol 2010; 17(9-10). 380-383.
247. Drexel H., Saely CH. Hypertonie bei Typ-2-Diabetes: Welche Medikation führt zum Ziel? Universum Innere Medizin 2010; 8: 40-42.

248. Saely CH, Drexel H. Prognostischer Stellenwert des HbA1c (2) – Evidenz aus makrovaskulären Endpunktstudien. Diabetes Forum 2010; 4: 40-44.
249. Drexel H. Prävention makrovaskulärer Komplikationen. Diabetes Forum 2010 Sonderausgabe: 28-32.
250. Saely CH, Mathies R, Drexel H. Strategien zur Verlangsamung der Atheroskleroseprogression. Universum Innere Medizin 2010; 9: 14.
251. Saely CH, Mathies R, Drexel H. Diabetes Typ 2 – Strategien zur Verlangsamung der Atheroskleroseprogression. Universum Innere Medizin 2010; 9: 14-16.
252. Saely CH. Bluthochdruck kann zu Erektionsstörungen führen. Lust und Frust. Forum Gesundheit 2010; 5: 33.
253. Drexel H. Experten-Statement: Einmal wöchentlich Exenatid (Bydureon® ): Studienlage und Einschätzung österreichischer Experten. MEDahead, Juni 2011.
254. Drexel H. Experten-Statement: Mit Ticagrelor (Brilique TM) die kardiovaskuläre Mortalität von Patienten mit akutem Koronarsyndrom senken. MEDahead advice Kardiologie, 2011:9.
255. Drexel H. Experten-Statement: Stellenwert von Twynsta® (Telmisartan + Amlodipin) im Management der Hypertonie. Update Europe, Internationale Zeitschrift für ärztliche Fortbildung 8/August 2011.
256. Drexel H. Workshop Angiopathie – Umfassende Gefäßprotektion bei Typ-2-Diabetes. In: Die Gefäße im Fokus – Internisten-Symposion & Workshops, Schloss Fuschl Resort
257. Saely CH, Drexel H. Diabetes und pAVK – Brauchen wir den Ankle-Brachial-Index? JATROS Diabetes & Stoffwechsel 4/2011;8-9.
258. Drexel H. Experten-Statement: Stellenwert der oszillometrischen Messung des Ankle Brachial Index (ABI) bei Patienten mit Verdacht auf pAVK. Update, Internationale Zeitschrift für ärztliche Fortbildung 7/Juni 2011.
259. Beer S. Individuelle Therapie der postmenopausalen Osteoporose. Endokrinologie & Stoffwechsel. Universum Innere Medizin 03/11, 30-31.
260. Drexel H, Saely CH. Glitazone: Was jeder Kardiologe wissen sollte. Skriptum Kongressjournal, Wiener Medizinische Wochenschrift 1/2011, 14-16.
261. Drexel H. Expertenforum: Stellenwert von Dronedaron bei Vorhofflimmern. Universum Innere Medizin 04/11, 32.
262. Saely C, Drexel H. Unterzucker bei Insulintherapie. Ärzte Woche (22) 2011, 25. Jg.: 14.
263. Saely CH, Drexel V, Vonbank A, Drexel H. Lipid management in Type 2 diabetes: the case for combination therapy? Therapy 8 (2) 2011: 129-141
264. Drexel H, Saely CH, Rein P. Aktuelles aus der kardiometabolischen Forschung. Universum Innere Medizin, 2011; 3:Expertenforum.

265. Drexel H, Saely CH. Strategien der intensivierten Lipidtherapie. *Universum Innere Medizin*, 2011; 2:32-36.
266. Drexel H. Disease Management des Typ 2 Diabetes – Hypertonie: Welche Medikation führt zum Ziel? *Arzt & Praxis*, 2011; 65 (973): 92-94.
267. Drexel H, Saely CH. Statine als Basis des modernen Lipidmanagements - Strategien der intensivierten Lipidtherapie. *Universum Innere Medizin*, 2011; 2: 18-20.
268. Gahr S, Saely CH, Drexel H. *Ernährungsumschau* 03/2012: 148-153.
269. Drexel H. Stellenwert der Therapie mit Mischinsulin bei Typ-2-Diabetes. *MEDahead Report* 2012.
270. Drexel H. Medizinischer Newsletter für zukunftsorientierte Ärzte. Der Typ-2-Diabetiker – ein kardiovaskulärer Hochrisikopatient. *MEDahead Report*, Expertenkommentar 2012
271. Drexel H. Expertenfrage: Pioglitazon – Mythen und Fakten: Stellenwert von Pioglitazon in der Therapie des Typ-2-Diabetes, *Universum Innere Medizin* 9/12
272. Drexel H. Erfolgsgeschichte Diabetologie. *Apothekerkrone* 20/2012: 21 – 23.
273. Saely CH. Lipidtherapie in der Angiologie. *MEDahead Positionspapier* 9/2012:1-6.
274. Drexel H. Die Feinde der Arterien – wie halte ich sie im Zaum?  
*Universum Innere Medizin* 07/12: 24.
275. Saely CH, Drexel H. Sicherheit und Effektivität in der Diabetestherapie: orale Antidiabetika. *Jatros Diabetes und Stoffwechsel* 3/2012: 8-9.
276. Drexel H. Erfolgreiche Diabetestherapie in Österreich. *Jatros Diabetes und Stoffwechsel* 3/2012: 6-7.
277. Positionspapier. Pharmakologische Spezifika und klinischer Stellenwert von Linagliptin (Trajenta®) bei Typ-2-Diabetes. *MEDahead* März 2012 (in press).
278. Interview mit Drexel H, Clodi M. Therapie: „aktiv“? *ADA Journal* 01/2012:6-7.
279. Drexel H. ÖDG Aktuell - Ausblick auf die Funktionsperiode 2012/2013. *DIABETES FORUM* 1/2012:7.
280. Drexel H. Kardiovaskuläres Risiko. *Suppl. Ärztemagazin Takeda Diabetesforum* 2012;
281. Drexel H, Saely CH. Strengere Zielwerte für Hochrisikopatienten sind sinnvoll. *Universum Innere Medizin*. 05/12:52.
282. Beer S, Drexel H. Individuelle Therapie der postmenopausalen Osteoporose. *Ärztekrone Osteoporose*/2012:12.
283. Drexel H. Saely CH. Zum Geleit – Was erwartet Sie in diesem Heft? *Diabetes Forum* 3/2012:25.



284. Saely CH, Drexel H. Lipidtherapie bei Diabetes – Warum ein LDL-Cholesterin von < 70 mg/dl? Diabetes Forum 3/2012:38-40.
285. Sturn D, Saely CH, Drexel H. Diabetes und Herzinsuffizienz – Neue Therapieansätze. Diabetes Forum 3/2012:48-51.
286. Drexel H, Saely CH. Strategien der intensivierten Lipidtherapie. Ärzte Krone 20/12: 30–32.
287. Drexel H. Kampf gegen Kalorien: Steuern mit Steuern? Ärzteswoche 2013; 50-52: 2.
288. Saely CH. Expertenmeeting: Doppelfunktion des Pankreas - Interaktionen zwischen exokriner und endokriner Funktion, Diagnostische Herausforderungen. Veranstaltungsreport 2013 bei der 41. ÖDG Jahrestagung: 3.
289. Drexel H. Statine auch bei Methusalem hilfreich. Ärztemagazin 2013; 27: 41.
290. Drexel H und Saely CH. Neues zum Welt-Diabetes-Tag - L wie Lebensstil und LDL-Cholesterin. Medical Tribune 2013; 49: 21.
291. Drexel H, Mohr M. Süß mit bitterem Beigeschmack. VN; 14.11.2013.
292. Drexel H. Stabile und instabile KHK. Universum Innere Medizin ÖGIM 07/13: 10-11.
293. Drexel H. Stabile und instabile KHK. Ärzteswoche Spezial ÖGIM 39: 32.
294. Saely CH. Hochdrucktherapie – Was bringt die Zukunft? LDL: The lower, the better. Ärztekronen 19; 12-13.
295. Drexel H. Thrombozytenaggregationshemmung: Womit? Wieviel ist genug? Was ist zuviel? Riport 73:4.
296. Schmid F, Saely CH, Drexel H. Metabolisches Syndrom und antihypertensive Therapie. J Hypertonie; 17: 59-64.
297. Saely CH. Expertenkommentar. Bedeutung der kombinierten Lipidsenkung für die Zielwerterreichung und das kardiovaskuläre Risiko. 04/13.
298. Drexel H, Saely CH. Die Relevanz der Lipidtherapie beim pAVK-Patienten: Statine als Behandlungsgrundlage. Universum Innere Medizin 2/13: 63.
299. Drexel, Saely CH. Highlightbericht über die ÖDG-Frühjahrstagung, „Fortschritte in klinischer Diabetologie und Endokrinologie“. Universum Innere Medizin 03/13: 58-59.
300. Drexel H. Interview mit Peter Hopfinger hinsichtlich ÖDG Präsidentschaft und ÖDG-Frühjahrstagung 2013. Diabetes Austria April 2013
301. Saely CH, Drexel H. Medikamentös induzierter Diabetes. Ärzteswoche 2013; 18: 14.
302. Drexel H, Säly CH. Die Relevanz der Lipidtherapie beim PAVK-Patienten -- Statine als Behandlungsgrundlage. Universum Innere Medizin 02/2013: 42.
303. Gouya G., Saely CH, „Hochdrucktherapie – was bringt die Zukunft? und „Aktuell gültige Guidelines zum Lipidmanagement“. Ärztekronen 19/13: 12-15.

304. Saely CH. Schlaganfallprävention bei Vorhofflimmern: DOAKs aus der kardiologischen Perspektive. Medical Tribune 2014; 44: 16.
305. Drexel H. Editorial: Elevation of HDL – Will the promise be fulfilled? Journal für Kardiologie 2014; 21: 251-252.
306. Drexel H, Saely CH. Paradigmenwechsel in der Lipidtherapie. Universum Innere Medizin 02/2014: 39-43.
307. Drexel H., Saely CH. Neue Antidiabetika: Bedeutung der Glukosesenkung im Management des Typ 2 Diabetes. Medinfo Ärzteverlag 2014. 4(3): 18-20.
308. Drexel H. Kardiodiabetes – Was gibt es Neues? Skriptum Wiener Medizinische Wochenschrift 1/2014: 22.
309. Drexel H. Kommentar zu LDL-C-Zielwerterreichung: Es gibt noch viel zu tun. Universum Innere Medizin 1/2014: 41.
310. Saely CH. Expertenmeeting: Doppelfunktion des Pankreas - Interaktionen zwischen exokriner und endokriner Funktion, Diagnostische Herausforderungen. Veranstaltungsreport 2013 bei der 41. ÖDG Jahrestagung: 3.
311. Drexel H. Expertenkommentar zu „Mit Brilique TM (Ticagrelor) die kardiovaskuläre Mortalität von Patienten mit akutem Koronarsyndrom senken“: MEDahead Publikation 2014: 8.
312. Consensus Statement; Expertenboard-Meeting Oktober 2014 in Wien: Die optimale Therapie der Thrombozytenaggregationshemmung, Expertenkommentar: 1-4.
313. Saely CH. LDL-Cholesterin: „The lower, the better“. Nephro Script 4/2015: 12-15.
314. Lhotta K. Der Kardiologe sagt: Harnsäure runter, was sagt der Nephrologe? Überlegungen zum Management bei kardiovaskulären Hochrisikopatienten. Nephro Script 4/2015: 10-11.
315. Zitt E. Parathyreoidektomie – was bringt es? Nephro Script 4/2015: 18-20.
316. Saely CH. Stellenwert der Triglyzeridsenkung im modernen Lipidmanagement. Expertenkommentar. MEDahead report Kardiologie 2015.
317. Saely CH. Familiäre Hypercholesterinämie im Fokus. Intern (Journal des Berufsverbandes Österreichischer Internisten) 1/2015; 1-8.
318. IMPROVE-IT has proven it: noch niedriger ist noch besser. Expertenkommentar. Universum Innere Medizin 1/2015:58-61.
319. Vonbank A. Kardiovaskuläre Risikofaktoren als Therapieziel. Diabetesforum 3/2015: 50-51.
320. Saely CH, Vathie K, Drexel H. Ischemic heart disease in diabetes. Textbook of diabetes and ischemic heart disease 2016
321. Saely CH. Konsequente LDL-Cholesterinsenkung für den kardiovaskulären Patienten. Je niedriger, desto besser. WMW Skriptum. Band 13/ Heft 01

322. Saely CH. Kardiovaskuläre Trials mit Antidiabetika - Löst die Glukosesenkung das Problem? Der informierte Arzt 2016; 6: 16-19.
323. Drexel H, Saely CH. Kardiovaskuläre Effekte von SGLT-2-Hemmern. Der Diabetologe 2016; 12(3), 195-200. DOI 10.1007/s11428-016-0079-4
324. Drexel H, Scherbaum WA. Kardiovaskuläre Effekte von Antidiabetika. Der Diabetologe; 12(3), 150-153. 10.1007/s11428-016-0089-2
325. Wascher TC, Paulweber B, Toplak H, Saely CH, Drexel H. Lipids: diagnosis and therapy in type 2 diabetes. Wien Klin Wochenschr 2012; 124, Suppl 2: 28-30.